2024 · Journal of mass spectrometry and advances in the clinical lab · open access
A high-throughput LC-MS/MS assay for piperaquine from dried blood spots: Improving malaria treatment in resource-limited settings
Blessborn et al.
The finding, in our words
A validated high-throughput LC-MS/MS assay for piperaquine from dried blood spots achieved 54-72% recovery with <9% relative standard deviation and a quantification limit of 3 ng/mL, enabling detection for 4-8 weeks post-dose. The method showed minimal haematocrit interference and is suitable for therapeutic drug monitoring of antimalarial treatment in resource-limited settings and pediatric populations.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
The study developed and validated a rapid LC-MS/MS method for quantifying cefazolin in capillary whole blood collected via VAMS, plasma, and plasma ultrafiltrate, showing robust performance across matrices and successful application in a pediatric pilot cohort for therapeutic drug monitoring.
The authors validated a UPLC-PDA assay for ceftazidime in 10 microlitre dried blood spots collected with the Capitainer device from neonatal patients, achieving accuracy of 90.1 to 104.8 per cent and precision within 11.7 per cent coefficient of variation across a quantification range of 0.5 to 200 micrograms per millilitre, and confirmed the method worked on clinical neonatal samples. This supports microsampling-based therapeutic drug monitoring of an antimicrobial in a vulnerable population where conventional venous blood draws are difficult.
The honest counterpoint in children: VAMS predicted plasma vancomycin only modestly, venous/arterial VAMS was more accurate than capillary, and 29% of capillary samples were unusable for collection issues: collection technique and training matter as much as the assay.
This review summarises liquid chromatography with tandem mass spectrometry assays using dried blood spots and volumetric absorptive microsampling for quantifying antimicrobial drugs in children, highlighting that VAMS reduces haematocrit bias and offers a viable alternative to traditional plasma sampling for therapeutic drug monitoring.
The validated LC-MS/MS method showed similar pharmacokinetic profiles for albendazole and its metabolites across plasma, whole blood, dried blood spots and Mitra microsamples from hookworm-infected adolescents, supporting microsampling for paediatric pharmacokinetic studies. Mitra extraction proved more robust than dried blood spots during validation and is recommended for future albendazole pharmacokinetic work, despite higher albendazole sulfone concentrations observed in both microsampling devices compared with wet matrices.